Curium announced on August 3, 2026 that it had entered into a definitive agreement to merge with Lantheus Holdings, Inc. (NASDAQ: LNTH) in an all-cash transaction valued at up to approximately $8Bn. Lantheus shareholders will receive $102.50 per share in cash at closing plus contingent value rights (CVRs) of up to $12.00 per share tied to commercial milestones through 2030, implying potential maximum consideration of approximately $114.50 per share. The combination brings together two of the larger independent radiopharmaceutical businesses and will return Lantheus to private ownership.

Controlled by CapVest Partners LLP, Curium operates more than 80 manufacturing sites and serves more than 70 countries with a portfolio of over 45 products. The transaction appears designed to assemble a company spanning the full nuclear medicine value chain, from isotope production and manufacturing through diagnostic imaging and targeted radioligand therapy. It is among the larger healthcare transactions announced so far this year, and it is a useful indicator of how sponsors are currently underwriting specialty pharmaceutical assets.

Transaction Overview

The headline consideration is $102.50 per share in cash, with CVRs that could add up to $12.00 per share depending on the performance of three franchises through the end of the decade. The milestones are tied to global prostate cancer diagnostics, global neurology diagnostics and the DEFINITY cardiac ultrasound business, with individual payments of $1.00 to $2.00 per share triggered at defined sales thresholds in fiscal years 2028 through 2030. The cash component represents a premium of approximately 38% to the 60-day volume-weighted average price and approximately 29% to the 30-day volume-weighted average price prior to announcement, and a premium of roughly 21% over the unaffected closing price as of May 21, 2026.

Curium expects to fund the transaction through a combination of debt and equity, and the agreement is not subject to any financing condition. Closing is expected in the first half of 2027, subject to Lantheus shareholder approval and regulatory clearances, and the Lantheus board has unanimously approved the merger following a review of strategic alternatives.

Strategic Rationale

Radiopharmaceuticals are unusual among pharmaceutical categories because the product decays, which means the supply chain is the business. An isotope produced in a reactor or cyclotron has to be processed, labeled, distributed and administered within hours to days, and the economics therefore favor operators with dense manufacturing and distribution networks rather than those with a single differentiated molecule. Curium’s roughly 80 manufacturing sites and Lantheus’s commercial franchises appear to be complementary along exactly that axis.

Lantheus contributes an established diagnostic portfolio, including PYLARIFY in prostate cancer imaging, DEFINITY in cardiac ultrasound and Neuraceq in beta-amyloid imaging, together with roughly seven decades of operating history in nuclear medicine. Curium contributes production capacity, international reach and sponsor capital. The stated rationale is theranostics, the pairing of a diagnostic agent that identifies patients with a therapeutic agent that treats them, and a combined company that controls both sides of that pairing may be better positioned than a company that controls only one.

Competitive Positioning in Nuclear Medicine

The radiopharmaceutical market has attracted substantial strategic interest over the past several years, with large pharmaceutical companies acquiring development-stage radioligand therapy platforms at significant valuations. Those transactions have generally been bets on clinical assets. This one is closer to an industrial consolidation, and its logic depends on manufacturing scale, isotope sourcing and distribution density rather than on a single readout. That distinction may explain why a sponsor-backed operator rather than a large pharmaceutical company is the buyer.

The CVR structure is worth attention in its own right. By deferring up to $12.00 per share against sales thresholds in 2028 through 2030, the parties appear to have resolved a disagreement about the durability of the diagnostic franchises, particularly in prostate cancer imaging where competition has intensified. Contingent consideration of this kind has become a common bridge in healthcare transactions where the buyer and the seller hold different views of the forward revenue curve, and it frequently allows a deal to be signed without either side conceding the point outright.

Broader Implications for Healthcare M&A

The transaction suggests that private capital remains willing to underwrite large, leveraged healthcare platforms despite a financing environment that has been selective. A roughly $8Bn take-private funded with debt and equity, combined with a regulatory review that will last into 2027, requires considerable conviction about cash flow stability. For mid-sized public healthcare companies trading below where their sponsors’ models would value them, this transaction may be a meaningful data point.

It may also reflect a broader pattern in which specialized, infrastructure-heavy segments of healthcare are being consolidated by operators rather than by diversified pharmaceutical companies. Isotope supply, sterile manufacturing and cold-chain distribution are difficult to replicate, and they tend to reward consolidation. We would expect continued interest in assets with those characteristics, and we would expect contingent consideration to remain a standard feature of transactions where near-term competitive dynamics are unsettled.

Conclusion

The Curium-Lantheus merger is best understood as a supply chain transaction wearing the clothes of a pharmaceutical deal, and its success will likely depend on manufacturing integration and isotope reliability rather than on any single product. The structure, with a substantial cash component and a deferred contingent element, appears to be a reasonable resolution of a genuine valuation disagreement. For owners of specialized healthcare platforms, the transaction is a reminder that scarce physical capability continues to command a premium. DelMorgan & Co. will continue to follow consolidation in nuclear medicine and its implications for companies evaluating strategic alternatives.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.